skip to Main Content

CONKO-007: Chemoradiotherapy Improves Resectability in Locally Advanced Pancreatic Cancer

Post-induction chemoradiotherapy (CRT) improved resectability, when compared with chemotherapy alone, in patients with unresectable, locally advanced pancreatic cancer, according to research presented at the 2022 ASCO Annual Meeting.

These first results from the CONKO-007 trial revealed that R0 and circumferential resection margin (CRM)-negative resection rates were higher with CRT. However, overall survival (OS) outcomes were similar with CRT and chemotherapy alone.  Read more . .  .

Back To Top